Qilian International Holding Group (BGM) Competitors $12.84 +0.49 (+3.97%) Closing price 03:59 PM EasternExtended Trading$12.70 -0.14 (-1.09%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrendsBuy This Stock BGM vs. PCVX, CYTK, KRYS, RYTM, PTCT, SRPT, RNA, SWTX, RARE, and AKROShould you be buying Qilian International Holding Group stock or one of its competitors? The main competitors of Qilian International Holding Group include Vaxcyte (PCVX), Cytokinetics (CYTK), Krystal Biotech (KRYS), Rhythm Pharmaceuticals (RYTM), PTC Therapeutics (PTCT), Sarepta Therapeutics (SRPT), Avidity Biosciences (RNA), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry. Qilian International Holding Group vs. Vaxcyte Cytokinetics Krystal Biotech Rhythm Pharmaceuticals PTC Therapeutics Sarepta Therapeutics Avidity Biosciences SpringWorks Therapeutics Ultragenyx Pharmaceutical Akero Therapeutics Vaxcyte (NASDAQ:PCVX) and Qilian International Holding Group (NASDAQ:BGM) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, community ranking, earnings, risk and media sentiment. Which has more risk and volatility, PCVX or BGM? Vaxcyte has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Qilian International Holding Group has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Which has preferable valuation & earnings, PCVX or BGM? Qilian International Holding Group has higher revenue and earnings than Vaxcyte. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxcyteN/AN/A-$402.27M-$3.99-8.51Qilian International Holding Group$25.10M49.74-$1.44MN/AN/A Does the media prefer PCVX or BGM? In the previous week, Vaxcyte had 16 more articles in the media than Qilian International Holding Group. MarketBeat recorded 16 mentions for Vaxcyte and 0 mentions for Qilian International Holding Group. Vaxcyte's average media sentiment score of 1.41 beat Qilian International Holding Group's score of 0.00 indicating that Vaxcyte is being referred to more favorably in the media. Company Overall Sentiment Vaxcyte Positive Qilian International Holding Group Neutral Does the MarketBeat Community favor PCVX or BGM? Vaxcyte received 55 more outperform votes than Qilian International Holding Group when rated by MarketBeat users. CompanyUnderperformOutperformVaxcyteOutperform Votes5578.57% Underperform Votes1521.43% Qilian International Holding GroupN/AN/A Do insiders and institutionals have more ownership in PCVX or BGM? 96.8% of Vaxcyte shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by insiders. Comparatively, 58.7% of Qilian International Holding Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is PCVX or BGM more profitable? Qilian International Holding Group's return on equity of 0.00% beat Vaxcyte's return on equity.Company Net Margins Return on Equity Return on Assets VaxcyteN/A -23.53% -22.20% Qilian International Holding Group N/A N/A N/A Do analysts prefer PCVX or BGM? Vaxcyte currently has a consensus target price of $136.50, suggesting a potential upside of 302.06%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts clearly believe Vaxcyte is more favorable than Qilian International Holding Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxcyte 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Qilian International Holding Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryVaxcyte beats Qilian International Holding Group on 8 of the 14 factors compared between the two stocks. Get Qilian International Holding Group News Delivered to You Automatically Sign up to receive the latest news and ratings for BGM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BGM vs. The Competition Export to ExcelMetricQilian International Holding GroupPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.25B$6.48B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.11%P/E RatioN/A9.0626.7119.71Price / Sales49.74251.50386.13120.55Price / CashN/A65.8538.2534.62Price / Book2.106.456.774.50Net Income-$1.44M$143.98M$3.23B$248.22M7 Day Performance11.46%2.41%1.80%0.56%1 Month Performance15.21%4.56%11.10%13.17%1 Year PerformanceN/A-2.67%17.11%7.30% Qilian International Holding Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BGMQilian International Holding GroupN/A$12.84+4.0%N/AN/A$1.25B$25.10M0.00298Positive NewsGap UpPCVXVaxcyte3.0946 of 5 stars$31.59+1.4%$136.50+332.1%-53.9%$4.08BN/A-6.87160Positive NewsCYTKCytokinetics4.1531 of 5 stars$32.13+1.4%$74.44+131.7%-47.9%$3.84B$19.22M-5.97250KRYSKrystal Biotech4.9093 of 5 stars$139.43+5.5%$218.63+56.8%-24.1%$3.82B$333.45M46.63210Positive NewsRYTMRhythm Pharmaceuticals3.9428 of 5 stars$58.97+2.8%$75.38+27.8%+64.2%$3.65B$136.86M-13.62140Positive NewsPTCTPTC Therapeutics4.1848 of 5 stars$46.01+4.0%$61.92+34.6%+18.9%$3.65B$1.77B-7.751,410Gap UpSRPTSarepta Therapeutics4.8153 of 5 stars$36.37+0.3%$131.22+260.8%-69.0%$3.57B$2.23B29.10840Positive NewsAnalyst ForecastHigh Trading VolumeRNAAvidity Biosciences1.9199 of 5 stars$29.33+5.2%$66.38+126.3%+3.8%$3.53B$10.90M-10.18190Options VolumeSWTXSpringWorks Therapeutics2.3665 of 5 stars$46.12-0.3%$52.57+14.0%+7.5%$3.46B$191.59M-13.25230High Trading VolumeRAREUltragenyx Pharmaceutical3.9707 of 5 stars$36.09+2.8%$90.93+152.0%-12.7%$3.32B$590.69M-5.691,310Positive NewsAKROAkero Therapeutics3.8137 of 5 stars$41.53+4.2%$76.29+83.7%+138.9%$3.31BN/A-11.0730Insider TradeHigh Trading Volume Related Companies and Tools Related Companies PCVX Competitors CYTK Competitors KRYS Competitors RYTM Competitors PTCT Competitors SRPT Competitors RNA Competitors SWTX Competitors RARE Competitors AKRO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BGM) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qilian International Holding Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Qilian International Holding Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.